The purpose of the study is to evaluate the safety, tolerability, and effect of the medication on the activity of a clot‑helping protein known as Factor XI after eight weeks. Participants will receive a few injections over several weeks and will attend brief visits for simple check‑ups, including blood tests and basic heart monitoring, to track any side effects and how the drug behaves in the body.

Participants in the study will take an oral tablet. Some will receive different doses of KT-621, while others will receive a placebo. To ensure the results are fair, the study is double blind, meaning neither the participants nor the researchers know which specific treatment is being administered at any given time. The study is organized into different groups that receive their assigned medication simultaneously to compare how well the drug works and to monitor its safety profile.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Durvalumab and are still benefiting from it, according to their doctor. The study will monitor the safety and how well patients tolerate the treatment. In addition to Durvalumab, the study may also involve other medications such as Infliximab and Mycophenolate Mofetil, which are used for different purposes. Infliximab is administered through an infusion, while Mycophenolate Mofetil is taken orally in capsule form.

Participants in this study will continue to receive their treatment as long as they are benefiting from it. The study will keep track of any serious side effects that occur up to 90 days after the last dose of the study treatment. This trial aims to ensure that patients who are doing well on their current treatment can continue to receive it safely.

Participants are randomly assigned to receive either belumosudil tablets taken by mouth or one of the comparator medicines chosen by their doctor. The study lasts about 24 weeks, during which regular clinic visits are scheduled to check symptoms, perform blood tests, and assess overall health. Researchers look at the overall response rate, which means the percentage of people whose disease shows improvement, using standard doctor‑approved guidelines (NIH consensus response criteria). Systemic therapy refers to medicines that work throughout the whole body, and any need for new systemic treatment, relapse of the underlying disease, or death is recorded.

Throughout the trial, safety is closely monitored; blood samples are taken to measure drug levels and to watch for side effects. Participants can stop the study at any time if they experience problems. The information gathered will help determine whether belumosudil works better and is safe for people with this condition.

The purpose of the study is to see if GSK6042981 works better than sunitinib malate in slowing down the growth of the cancer or stopping it from getting worse. Patients taking part in this study will be randomly assigned to receive either GSK6042981 or sunitinib malate, and both groups will know which medicine they are receiving. During the study, doctors will monitor how well the treatment is working and how long patients can go without their disease getting worse. Patients will also be asked about their quality of life and any side effects they may experience.

Throughout the study, doctors will collect tissue samples from tumors for laboratory testing, which may come from previously stored tissue or from a new biopsy. The study will also measure the levels of GSK6042981 in the blood and track various aspects of patient health, including how long patients live, how quickly the tumor responds to treatment, and whether the cancer gets worse after starting a different treatment following the study medicine. Patients will complete questionnaires about their symptoms and overall well-being to help researchers understand how the treatments affect daily life.

The purpose of the trial is to determine whether the new medicine works as well as, or better than, the standard treatment in patients who have not received prior therapy for this condition. This phase 3 investigation uses a randomized, open-label design, meaning participants are assigned by chance to one of the two drugs and both the study team and participants know which drug is being taken. After enrollment, participants receive daily medication and attend regular clinic visits for safety checks and imaging scans that monitor the tumor. The study follows each person until the cancer shows signs of worsening, which is measured as progression-free survival, or until side effects require stopping the medication.

The main goal of the study is to see if the injectable letrozole works better than the oral Femara when both are given with ribociclib. Participants will be randomly assigned to one of the two treatment groups and will take the study medicines for several months, with regular check‑ups to monitor how the cancer is responding and to watch for side effects. The study does not involve any surgical procedures; all medicines are taken by mouth or by a simple injection into the muscle.

After the first dose, participants will return for clinic visits every few weeks during the first few months, then roughly every two to three months for the rest of the study. At each visit doctors will ask about symptoms, perform basic physical exams, and may order imaging tests such as scans to see if the cancer has grown or shrunk. The study continues until the cancer progresses, unacceptable side effects occur, or the participant chooses to stop.

The purpose of the trial is to evaluate the clinical efficacy of frevecitinib. Over a period of about three months, participants will take the study medication each day and attend clinic visits at the start of the study and at weeks 2, 4, 8 and 12. During these visits lung function will be measured using tests such as FEV1, which records how much air can be forced out of the lungs in one second, and symptom questionnaires will be completed.

Safety will be monitored throughout the study with regular checks of blood tests, heart rhythm recordings (ECG), blood pressure, and reports of any adverse events. Participants will continue their regular asthma inhalers while using the study powder, and any changes in rescue inhaler use or asthma symptoms will be recorded.

Participants are randomly assigned to receive either the study drug or placebo on a regular schedule for several months. Throughout the trial, blood tests are performed to measure thyroid hormones (such as T3, T4, and TSH) and antibodies that affect the thyroid (TRAb). Researchers also monitor overall health, side effects, and quality of life using questionnaires. The study follows participants for up to 24 weeks to see how many can maintain normal thyroid function without antithyroid drugs and to assess any safety concerns associated with the treatment.

Participants receive the subcutaneous injection of Xembify once a week at a dose based on body weight, while a separate group receives the Gamunex® 10% infusion once every three weeks. The study continues for up to 39 weeks, during which safety is monitored and blood samples are taken to see how the body processes each medication. Terms such as “subcutaneous” mean under the skin, and “intravenous infusion” means the medicine is delivered slowly through a needle placed in a vein.

The purpose of the study is to determine the dose‑response relationship of UBT251, meaning how different amounts of the medicine change the level of HbA1c, a test that shows average blood sugar over the past few months, in people whose diabetes is not well controlled with metformin alone or together with a SGLT2 inhibitor.

Participants will receive weekly injections for about ten months and will attend regular clinic visits where blood samples are taken and body measurements are recorded. Some participants will receive the new drug, some will receive the existing drug, and some will receive the inactive substance. The study will track changes in blood sugar, weight, and other health markers over the course of the trial.

The purpose of this study is to evaluate how well XmAb942 works in helping people with moderately to severely active Ulcerative Colitis achieve clinical remission, which means bringing the disease under control so that symptoms improve significantly. The study is divided into two parts. The first part tests the medication in healthy volunteers to check its safety. The second part involves people who have moderate to severe Ulcerative Colitis and have not responded well to previous treatments, lost response to them, or could not tolerate them. Participants in the second part must have had Ulcerative Colitis for at least three months and show active disease with inflammation visible during examination of the bowel.

During the study, participants will be randomly assigned to receive either XmAb942 or placebo. The treatment period lasts up to 48 weeks, with an important assessment at week 12 to see if the medication is working. Doctors will measure improvement by looking at various signs of the disease, including bleeding, bowel movement frequency, and inflammation seen during bowel examination. The study will also monitor any side effects or unwanted reactions that occur during treatment to ensure the safety of participants.

The main aim of the trial is to assess the long‑term safety of the study drug, meaning how well it is tolerated over time and what side effects may occur. Participants who have already finished earlier studies receive the medication for an extended period, attending regular visits where health checks, blood tests and simple scans are performed. Any unwanted problems, called adverse events, are recorded and evaluated, with particular attention to serious issues that might require medical care.

The main aim of the trial is to find out whether the new drug behaves the same way in the body as the approved medicine. Participants receive the assigned infusion on a set schedule, with clinic visits for blood draws, simple heart checks, and occasional scans to look for any signs that the cancer has come back. Doctors also watch for any side effects and record any changes in laboratory tests.

After the treatment period, participants continue to be followed for up to a year to see how long they stay free of cancer and to monitor safety. The study records any problems that arise, checks hormone and blood levels, and measures the body’s response to the drug. All information is kept confidential and used only to understand the medicines better.

The purpose of the study is to see how well Concizumab works in preventing bleeding episodes compared to the previous treatment the children were receiving. The study will involve children who have not used Concizumab before. Participants will receive regular injections of Concizumab over a period of time, and the number of bleeding episodes they experience will be monitored and compared to their previous treatment.

Throughout the study, researchers will also keep track of any side effects or reactions to the medication, such as injection site reactions or the development of antibodies against Concizumab. The study aims to provide valuable information on the safety and effectiveness of Concizumab in managing bleeding episodes in young children with hemophilia.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

Participants are randomly assigned to receive either the test drug or placebo for about three months, and neither the participants nor the study staff know which treatment is given, a design known as double-blind. After the initial 12‑week period, the study continues for an additional 40 weeks in a phase where participants may switch to other antipsychotic medications or continue the study drug, using a “double‑dummy” approach to keep the blind intact. Throughout the trial, safety checks and simple questionnaires are performed at regular visits to monitor how participants feel and whether any problems develop.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

During the trial, participants will take the study medication once daily for about 24 weeks. They will attend regular clinic visits where blood samples are drawn to measure hormone levels and safety checks are performed. The study follows a straightforward schedule of visits and tests, allowing researchers to observe changes in hormone levels over time without requiring any invasive procedures.

Participants will receive the injection regularly for a total of 16 weeks and will attend clinic visits where doctors will check their health, perform simple blood tests, and monitor heart rhythm with a standard heart‑monitoring strip (ECG). One of the key measurements is pulmonary vascular resistance, a number that shows how hard the heart has to work to push blood through the lungs. Other assessments include measuring oxygen saturation (the level of oxygen in the blood) at rest and during a 6‑minute walk test, where the distance a person can walk in six minutes is recorded and the drop in oxygen levels is tracked. Throughout the study, any side effects or unusual lab results will be recorded to assess safety.

The purpose of the trial is to find out whether early use of depemokimab can lower the number of worsening episodes and keep asthma under better control. Participants will be randomly assigned to receive either the study drug or the placebo, with injections administered in a clinic setting every six months. Over a period that may extend up to three years, they will attend regular visits where doctors will check symptoms, record any serious attacks, and perform simple breathing tests.

During the study, several easy‑to‑understand tools are used: the ACT questionnaire asks about daily symptoms, the AQLQ asks how asthma affects quality of life, and the ACQ-5 measures recent symptom severity. Lung capacity is measured with a test called FEV1, which shows how well the lungs move air in and out, providing an overview of overall lung function. Safety checks are also performed at each visit to monitor how participants tolerate the treatment.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

The aim of the study is to evaluate the safety and tolerability of long‑term use of this medication. Participants who have previously taken part in an earlier trial will continue to receive the inhaled powder and will be followed for up to two years. During this time they will attend regular clinic visits where simple checks such as blood tests, heart rhythm monitoring (ECG), measurement of oxygen use, and basic physical examinations are performed. The study also includes a group receiving placebo for comparison.

Throughout the study, participants will undergo a short walking test (6MWD) to see how far they can walk in six minutes, and lung function tests that measure the amount of air they can force out (FVC) and the speed of airflow (FEV1). Blood samples will be taken to check levels of a heart‑stress marker (NT-proBNP). These assessments help researchers understand how the medication affects breathing ability, heart strain, and overall health over the long term.

The main purpose of the study is to determine whether Enpatoran can lower skin disease activity. Participants will take the study medication daily for about 24 weeks and will attend regular clinic visits to check their skin and overall health. Skin severity will be measured with a tool called the CLASI, which gives a number based on how much of the skin is affected and how severe the rash is. Overall lupus activity may also be evaluated using the BICLA score. Safety will be monitored by recording any side effects, referred to as TEAEs. The study will finish after the 24‑week period, and the results will show whether the drug provided a meaningful improvement.

The purpose of the study is to find out if the medicine can reduce skin thickening. Participants will receive the assigned treatment every few weeks for about six months, with regular visits to check safety and to measure skin changes using the modified Rodnan skin score, a simple scale doctors use to rate how tight the skin feels. Small blood samples and occasional skin samples may be taken to look for any reactions, and any side effects will be recorded throughout the study.